Top Markets
Coin of the day
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
Rangering i aksjer #40868
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Aksjekurs
$0.02765
Sist synkronisert: 2024-12-23
Markedsverdi
$69.04K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Histogen Inc. (HSTO)

Kategori

Inntekter for Histogen Inc. (HSTO)
Inntekter i Sep 2023 TTM: $19.00K
Ifølge de nyeste økonomiske rapportene til Histogen Inc. er selskapets nåværende inntekter (TTM) $19.00K. I 2021 hadde selskapet inntekter på $919.00K en nedgang sammenlignet med inntektene i 2020, som var $2.06M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Histogen Inc. fra 2011 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $19.00K -99.50%
2022 $3.77M 310.12%
2021 $919.00K -55.37%
2020 $2.06M -82.02%
2019 $11.45M -65.90%
2018 $33.59M -5.06%
2017 $35.38M 4,327.40%
2016 $799.05K 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$12.62B 66,443,584.21%
US
$6.02B 31,690,885.84%
NL
- -
CH
- -
KR
$10.11B 53,214,566.82%
BE